简介：目的探讨一种规范化的的高度近视白内障超声乳化方式,总结手术注意点。方法选取高度近视白内障患者91例（91眼）均予以超声乳化联合人工晶体植入术治疗并总结。结果所有病例的术后裸眼视力均优于术前裸眼视力。术后第1天裸眼视力≥0.2共72眼（79.12%）,≥0.5共37只眼（40.66%）;术后3月裸眼视力≥0.2共85只眼（93.41%）,≥0.5共42只眼（46.15%）。最佳矫正视力≥0.2共89只眼（97.80%）,最佳矫正视力≥0.5共72只眼（79.12%）。术前散光度平均1.10D±0.78D,术后3月散光度平均1.25D±0.72D。术后散光度与术前散光度比较,差异无显著性（t=1.166,P=0.261）。无瞳孔严重变形、视网膜脱离、囊样黄斑水肿、瞳孔夹持、青光眼以及顽固性葡萄膜炎等并发症。结论低能量,高负压,低灌注,连续环形撕囊,双手劈核技术对于高度近视白内障患者更加安全有效。

简介：目的：评价图形视觉诱发电位（patternvisualevokedpotentials,P-VEP）、眼底照相、视野和光学相干断层扫描（opticalcoherencetomography,OCT）对青光眼患者检查的可靠性。方法：对83例95眼青光眼患者应用眼科电生理仪、眼底照相、视野和OCT,根据P-VEP、眼底照相、OCT、视野检查结果的阳性率进行相关性分析。结果：患者83例95眼中,视野检查成功获取阳性病例图像73眼（76.8%）,无法获取图像22眼（23.2%）;眼底照像成功获取阳性病例图像75眼（78.9%）,无法获取图像20眼（21.1%）;获得P-VEP阳性病例47眼（49.5%）,未见明显异常26眼（27.3%）,无法采集图像22眼（23.2%）;成功获取OCT阳性病例图像81眼（85.3%）,无法获取OCT图像14眼（14.7%）。结论：视觉诱发电位、眼底照相、视野和光学相干断层图像结果对青光眼患者的视功能状况进行综合评估。

简介：AIM:Toadaptthelowvision-relatedqualityoflife(LVQOL)instrumentintoTurkishlanguageandtoassessitsvalidityandreliability.METHODS:Thestudywasconductedin387patientsattendingtheCentreofLowVisionRehabilitation,FacultyofMedicine,AnkaraUniversity.Forstatisticalanalyses,theSpearman’scorrelationcoefficient,Cronbach’salphacoefficientandConfirmatoryFactorAnalysis(CFA)wereused.RESULTS:AccordingtoresultsofCFA,theiteminthe'Adjustment'subscalebecauseofhavingthefactorloadingbelow0.40,wasexcludedfromthequestionnaire.ThereliabilityofthequestionnairewasassessedaccordingtoCronbach’salphacoefficients.Thereliabilityofthe'DistanceVision,Mobility,andLighting'subscalewas?琢=0.863;ofthe'Adjustment'subscalewas?琢=0.694;'ReadingandFineWork'was?琢=0.791,and'ActivitiesofDailyLiving'was?琢=0.770.Sotheseresultsindicatethatthequestionnaireisreliabletomeasurethevisionrelatedqualityoflifeoflow-visionpatients.Thecorrelationsbetweenthesubscaleswerealsoanalyzed,andthecorrelationbetween'Adjustment'and'ReadingandFineWork'wasfoundtobethelowest(rs=0.336,P<0.001),whereasthestrongestcorrelationwasfoundbetweenthe'ReadingandFineWork',and'ActivitiesofDailyLiving'.Additionally,the'Adjustment'dimensionshowedthestrongestcorrelationwithonly'DistanceVision,Mobility,andLighting'dimension.CONCLUSION:Afterremovingthelastitemintheseconddimension,theTurkishadaptationofalldimensionsoftheLVQOLhasbeenshowntobereliable,validandsuitableforuseinpatientswithlowvisioninTurkey.

简介：目的：系统评价拉坦前列素（Latanoprost）滴眼液与噻吗心安（Timolol）滴眼液降眼压的有效性和安全性。方法：计算机检索PubMed，Medline，CNKI及中国生物医学文献数据库收录的，并辅以手工检索、因特网搜索的有关拉坦前列素与噻吗心安治疗原发性开角型青光眼和高眼压症的随机对照试验（RCT）。按照纳入和排除标准限定研究对象，通过Jadad评分量表进行文献质量评估后，针对眼压下降比例、药物不良反应2项内容，使用Cochrane协作网提供的RevMan5．0软件进行Meta分析。结果：共纳入9项RCT，合计555例患者。Meta分析结果显示：（1）拉坦前列素滴眼液与噻吗心安滴眼液降眼压效果，在2，6，12wk时差异均有统计学意义（P＜0．01），加权平均差（WMD）分别为：在2wk[WMD＝-0．76，95％CI（-1．32，-0．20）]，在6wk[WMD＝-1．15，95％CI（-1．68，0．63）]和12wk[WMD＝-1．01，95％CI（-1．42，-0．61）]。（2）随访结束时，结膜充血、异物感为拉坦前列素的两种较为常见的不良反应，但其发生率拉坦前列素组与噻吗心安组比较，结膜充血的发生率[OR＝2．25，95％CI（0．99，5．08）]，异物感的发生率[OR＝2．48，95％CI（1．02，6．03）]，显示二者差异均无统计学意义。结论：治疗原发性开角型青光眼和高眼压症，拉坦前列素降眼压效果在用药12wk内较噻吗心安好；两者在12wk内引起结膜充血、异物感、虹膜色素加深、视野损害等的不良反应方面，差异不明显。由于纳入研究的样本量偏小，且方法学质量中等，致使本系统评价结果论证强度不高，因此还需要开展更多的高质量的临床随机对照研究，以便更客观、准确、全面地评价其疗效和安全性。

简介：AIM:Tofindouttheoutcomeoflaserphotocoagulationinclinicallysignificantmacularedema(CSME)byopticalcoherencetomography(OCT).·METHODS:Itwasaprospective,non-controlled,caseseriesstudyenrolling81eyesof64patientswithCSMEbetweenAugust2008andJanuary2010.AllpatientsreceivedmodifiedgridphotocoagulationwithfrequencydoubledNd:YAGlaser.Eachpatientwasevaluatedintermsofbest-correctedvisualacuity(BCVA)andregressionorprogressionofmaculopathyafterlasertherapyat1,3and6months.Spearman’scorrelationtestwasusedtoshowthecorrelationbetweenBCVAandtotalmacularvolume(TMV).Analysisofvariance(ANOVA)wasusedtocompareamonggroupsandindependentt-testwasusedtocompareineachgroup.·RESULTS:ThereishighcorrelationbetweenBCVAandTMV(P≤0.001).BCVAimprovedin50.6%,remainedstaticin39.5%anddeterioratedin9.9%patientsafter6monthoftreatment.TheBaselineTMV(meanandSD)were9.26±1.83,10.4±2.38,11.5±3.05,8.89±0.75and9.47±1.98mm3fordifferentOCTpatterns,ST(spongelikethickening),CMO(cystoidmacularedema),SFD(subfovealdetachment),VMIA(Vitreomacularinterfaceabnormality)andaverageTMVrespectively(P=0.04).After6monthsoflasertreatment,themeanTMVdecreasedfrom9.47±1.98mm3to8.77±1.31mm3(P=0.01).InSTtherewassignificantdecreaseinTMV,P=0.01,Furtherwithinthesegroupsat6months,theyweresignificantlydifferent,P=0.01.·CONCLUSION:OCTshowedthedifferentmorphologicalvariantofCSMEwhiletheresponseoftreatmentisdifferent.TMVdecreasedthemostandhenceshowedtheimprovementinvisionafter6monthsoflasertreatment.IntheeraofAntivascularendothelialgrowthfactors(VEGFs),efficacyoflaserseemstobeinshadowbutitisstillfirstlineoftreatmentindevelopingnationlikeNepalwhereantiVEGFsmaynotbeeasilyavailableandaffordable.